Abuja — Abuja-based singer Ifunanya Nwangene, popularly known as “Nanyah,” has died after a snake bite at her residence, igniting public anger and renewed scrutiny of emergency care and anti-venom availability in Nigeria’s hospitals.
Who the singer is
Nwangene, 26, was an Abuja-based vocalist and a member of the Amemuso Choir, where she sang as a soprano. She was also reported to be a former contestant on The Voice Nigeria.
What happened (details so far)
Reports say Nwangene was bitten at home and rushed for care, but her condition deteriorated as efforts were made to obtain treatment. One account says she first sought help at a facility in Lugbe before she was taken to Federal Medical Centre (FMC), Abuja, where she later died on January 31, 2026.
A central point of dispute is whether anti-venom was available quickly enough:
- Witness account / initial reports: A friend and music director of the choir said doctors indicated she needed two doses of anti-venom, but only one was available at a critical moment, prompting a frantic search for another dose.
- Hospital’s position: FMC, Abuja has disputed claims that her death was due to lack of anti-venom, saying she died from a severe neurotoxic snake bite rather than non-availability of anti-snake venom.
Atlanticdigest note: Both versions are circulating widely; the hospital’s statement directly contradicts parts of the witness narrative, and this is the core of the controversy.
Why snakes are showing up more in cities like Abuja
Experts and emergency agencies have long warned that dry-season conditions, bush burning, and environmental disruption can push wildlife—including snakes—closer to human settlements in search of shelter, prey, and water. Abuja authorities have repeatedly cautioned residents during harmattan/dry season about wildfires linked to bush burning, which can also drive animals out of cover.
Why a hospital may not be able to treat with anti-venom
Even when clinicians know what’s needed, anti-venom access can fail for several systemic reasons:
- Supply shortages and weak distribution: Nigeria faces recurring anti-venom gaps, with frontline health workers warning shortages are undermining response capacity.
- Cost and constrained manufacturing: Investigations into Africa’s anti-venom market describe chronic under-supply, high prices, and fragile production pipelines as major barriers to availability.
- Treatment complexity: Snakebite management can require multiple vials and rapid timing; WHO notes anti-venoms are effective, essential medicines, but outcomes depend heavily on availability and accessibility.
What happens next
Key questions now are whether FMC will publish a fuller clinical account (without breaching patient confidentiality), and whether health authorities will address broader anti-venom stocking and emergency referral protocols—issues Nigerians say repeatedly turn treatable emergencies into tragedies.
Developing story: Atlanticdigest will update this report as more verified details emerge from the hospital, health authorities, and the family.
